| Clinical Study of Gastric Cancer, Colorectal Cancer and Bladder Cancer Based on Liquid Biopsy (NCT04385316) | The First Affiliated Hospital with Nanjing Medical University | 2019-09-01 |
| Development of Multiphasic CT-based Delta-Radiomics Model for Predicting Postoperative Recurrence Risk in Bladder Cancer (NCT07251946) | Lian Yang | 2019-08-01 |
| Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma (NCT04314245) | AnchorDx Medical Co., Ltd. | 2019-08-01 |
| First-in-human Study of S-588210 (S-488210+S-488211) (NCT04316689) | Shionogi | 2019-07-30 |
| Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies (NCT04149691) | Celon Pharma SA | 2019-07-19 |
| CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (NCT03933826) | University of Washington | 2019-07-09 |
| Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy (NCT04129606) | Abdelwahab Hashem | 2019-07-01 |
| Treatment of Recurrent Bladder Cancer With Dendritic Cells (NCT04184232) | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 2019-07-01 |
| Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) (NCT03924856) | Merck Sharp & Dohme LLC | 2019-06-13 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors (NCT04234113) | SOTIO Biotech AG | 2019-06-13 |
| Simulation in Transurethral Bladder Cancer Surgery (NCT03864302) | Rigshospitalet, Denmark | 2019-06-01 |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) (NCT03869190) | Hoffmann-La Roche | 2019-06-01 |
| Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy (NCT03993249) | Hellenic GenitoUrinary Cancer Group | 2019-05-28 |
| Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis (NCT03982797) | Biofabri, S.L | 2019-05-17 |
| A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors (NCT03960060) | Shanghai PerHum Therapeutics Co., Ltd. | 2019-05-16 |
| Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer (NCT03892642) | University of Oklahoma | 2019-05-01 |
| A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (NCT03872947) | Toray Industries, Inc | 2019-04-26 |
| Nosocomial Infections During Total Prostatic Cystectomies (TPC) With Replacement Enterocystoplasty: Prophylactic Role of Urell®, Cranberry Fruit Juice Extract (Vaccicium Macrocarpon) (NCT03986398) | Hopital Foch | 2019-04-14 |
| MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour (NCT03934827) | Imperial College London | 2019-04-10 |
| Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors. (NCT03335059) | Medical Enterprises Ltd. | 2019-04-04 |
| Evaluation of NanoDoce® in Participants With Urothelial Carcinoma (NCT03636256) | NanOlogy, LLC | 2019-04-02 |
| Comprehensive Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Non Muscle-invasive Bladder Tumor; Can it Replace Second Look Biopsy? A Prospective Study (NCT03914001) | Mansoura University | 2019-04-01 |
| Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (NCT03532451) | PrECOG, LLC. | 2019-03-22 |
| En-bloc vs Conventional Resection of Primary Bladder Tumor (NCT03718754) | David D'Andrea | 2019-02-28 |
| Basal Tumours in Bladder Cancer, Response to chemoTherapy (NCT04089748) | University Hospital, Rouen | 2019-02-27 |
| (CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer (NCT03837821) | Weill Medical College of Cornell University | 2019-02-05 |
| Prospective Study of Adjuvant Radiotherapy in High Risk Bladder Cancer. (NCT03718741) | Istituto Clinico Humanitas | 2019-02-05 |
| The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study (NCT04075305) | UMC Utrecht | 2019-02-01 |
| Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria (NCT05362539) | Mansoura University | 2019-02-01 |
| Trial of Open Versus Laparoscopic Radical Cystectomy at a Laparoscopic Naive Center (NCT04838873) | Cairo University | 2019-01-24 |
| UroX Biomarker Bladder Cancer Study (NCT03973307) | East and North Hertfordshire NHS Trust | 2019-01-21 |
| Patient-reported Outcomes in Bladder Cancer (NCT03584659) | Rigshospitalet, Denmark | 2019-01-21 |
| Sequential Combination Therapy in Bladder Cancer (NCT03790384) | Azienda Ospedaliera "Sant'Andrea" | 2019-01-15 |
| Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors (NCT03637803) | 4D pharma plc | 2019-01-10 |
| A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer (NCT03762161) | Rahul Parikh | 2019-01-03 |
| Can VI-RADS/ADC Accurately Stage Bladder Cancer?? (NCT04167631) | Mansoura University | 2019-01-01 |
| Expression of MCM5 in Urine in Patients With Urothelial Cancers (NCT03796299) | Medical University of Warsaw | 2019-01-01 |
| Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors (NCT03836352) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2018-12-21 |
| A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors (NCT03775850) | Evelo Biosciences, Inc. | 2018-12-19 |
| A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer (NCT03498196) | Baylor College of Medicine | 2018-12-14 |
| Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy (NCT03697850) | UNICANCER | 2018-12-14 |
| Avelumab and Radiation in Muscle-Invasive Bladder Cancer (NCT03747419) | Dana-Farber Cancer Institute | 2018-12-13 |
| The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy (NCT03831321) | Taha Uçar | 2018-12-11 |
| Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients (NCT03787056) | Hospices Civils de Lyon | 2018-12-04 |
| The Cxbladder Rule-out of Recurrent Urothelial Carcinoma (NCT03673202) | London Health Sciences Centre | 2018-11-26 |
| Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB) (NCT03534492) | Spanish Oncology Genito-Urinary Group | 2018-11-16 |
| Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer (NCT03759496) | Hellenic GenitoUrinary Cancer Group | 2018-11-15 |
| Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (NCT03621982) | ADC Therapeutics S.A. | 2018-11-09 |
| Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer (NCT03298958) | The University of Texas Health Science Center at San Antonio | 2018-11-01 |
| Multidisciplinary Bladder-preservation Therapy for Bladder Cancer (NCT03756207) | Peking University Third Hospital | 2018-11-01 |
| Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer (NCT03664869) | Turku University Hospital | 2018-10-26 |
| Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) (NCT03472274) | Fundacion CRIS de Investigación para Vencer el Cáncer | 2018-10-25 |
| Use of Immediate Hyperthermic Intravesical Chemotherapy Following TURBT (NCT03689478) | Chinese University of Hong Kong | 2018-10-22 |
| A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NCT03558503) | UroGen Pharma Ltd. | 2018-10-15 |
| Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NCT04060459) | Third Military Medical University | 2018-10-01 |
| Measuring and Improving the Safety of Test Result Follow-Up (NCT04166240) | VA Office of Research and Development | 2018-10-01 |
| A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors (NCT03693014) | Memorial Sloan Kettering Cancer Center | 2018-10-01 |
| Recovery Support for Bladder Cancer Patients and Caregivers (NCT04055311) | Northwell Health | 2018-10-01 |
| Glycosaminoglycan Scores as Early Detection Biomarkers in Bladder Urothelial Carcinoma (NCT05799456) | Jens Nielsen | 2018-10-01 |
| Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol (NCT03216525) | Brigham and Women's Hospital | 2018-10-01 |
| CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (NCT03628716) | Bavarian Nordic | 2018-09-18 |
| Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (NCT03534804) | University of Utah | 2018-09-18 |
| Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) (NCT04212403) | Jessa Hospital | 2018-09-17 |
| Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases (NCT03520231) | University Health Network, Toronto | 2018-09-04 |
| Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors (NCT03662204) | Exact Sciences Corporation | 2018-08-23 |
| Novel mRNA-based Urine Test for Bladder Cancer in Spinal Cord Injury Individuals (NCT02538809) | Swiss Paraplegic Research, Nottwil | 2018-08-13 |
| The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation (NCT03591367) | Mansoura University | 2018-08-01 |
| Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners (NCT03652298) | Centre Oscar Lambret | 2018-07-25 |
| A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies (NCT03629756) | Arcus Biosciences, Inc. | 2018-07-24 |
| The Difference of Two Year Recurrence Rate According to Anesthetic Method During Transurethral Resection of Bladder Mass in Patients With Non-muscle Invasive Bladder Cancer: Prospective, Randomized, Clinical Phase II Study (NCT03597087) | Seoul National University Hospital | 2018-07-19 |
| Implementation of Nutrition Education Videos for Patients Undergoing Radical Cystectomy (NCT03801954) | University of Kansas Medical Center | 2018-06-28 |
| Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)] (NCT03504163) | Memorial Sloan Kettering Cancer Center | 2018-06-27 |
| A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) (NCT03474107) | Astellas Pharma Global Development, Inc. | 2018-06-27 |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (NCT03397394) | pharmaand GmbH | 2018-06-01 |
| The Role of mRNA-based Urine Test (Xpert Bladder Cancer Monitor) in Predicting the Need for Second Look Biopsy After Transurethral Resection of Non Muscle-invasive Bladder Tumor. (NCT04603612) | Mansoura University | 2018-06-01 |
| The Accuracy of Optic Biopsies Versus Conventional Biopsies for the Diagnosis of Superficial Bladder Neoplasia (NCT02841904) | Herlev Hospital | 2018-06-01 |
| Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer (NCT03081858) | Lipac Oncology LLC | 2018-05-17 |
| Comparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal Neobladder (NCT03108196) | Zhujiang Hospital | 2018-05-02 |
| High-power Green-light Laser Endoscopic Submucosal Dissection for Non-muscle-invasive Bladder Cancer (NCT05290623) | Shandong Provincial Hospital | 2018-05-01 |
| A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy (NCT03520491) | Memorial Sloan Kettering Cancer Center | 2018-04-25 |
| Intracorporeal vs Extracorporeal Urinary Diversion After Robot Assisted Radical Cystectomy (NCT03469362) | University of Miami | 2018-04-25 |
| CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (NCT03454451) | Corvus Pharmaceuticals, Inc. | 2018-04-25 |
| The Effect of Goal-directed Hemodynamic Therapy in Radical Cystectomy (NCT03505112) | Seoul National University Hospital | 2018-04-20 |
| Bladder Tumor Biopsy Study to Improve Preoperative Determination of Stage and Grade (NCT02992990) | Baylor College of Medicine | 2018-04-01 |
| A Trial of a Modified Cystoscopy Method to Reduce Pain Perception (NCT03257293) | Western University, Canada | 2018-04-01 |
| En Bloc Bladder Tumor Resection: Prospective Randomized Study (NCT04712201) | Fundacio Puigvert | 2018-04-01 |
| Development and Validation of a Simulator-based Test in Transurethral Resection of Bladder Tumors (NCT03863028) | Rigshospitalet, Denmark | 2018-03-15 |
| Role of Novel Urinary Genomic and Metablomic Markers in Diagnosis of Bladder Cancer in Patients With Hematuria (NCT04317261) | Mansoura University | 2018-03-01 |
| Xpert Bladder Cancer Monitor; Prospective, Single, Tertiary-care Center Implementation Study (NCT03715660) | Mansoura University | 2018-03-01 |
| A Study Using MRI To Assess Bladder Motion During Radiotherapy (NCT03409029) | The Christie NHS Foundation Trust | 2018-03-01 |
| Assessment of BladderLight SurvEILlance (NCT03427034) | Cambridge University Hospitals NHS Foundation Trust | 2018-02-01 |
| Open Versus Robot Assisted Radical Cystectomy With Totally Intracorporeal Urinary Diversion. (NCT03434132) | Regina Elena Cancer Institute | 2018-01-29 |
| Assessment Of Bladder Tumors Stage And Grade By Outpatient Flexible Cystoscopy Performed By Urology Resident (NCT03148158) | Mansoura University | 2018-01-15 |
| Trimodal Prehabilitation for Cystectomy Patients to Enhance Post-operative Care (NCT03347045) | Jason Martyn | 2018-01-15 |
| Endo-GIA Versus Endowrist Stapler in Intracorporeal Urinary Diversion in Robotic Assisted Radical Cystectomy (NCT03385798) | Jørgen Bjerggaard Jensen | 2018-01-01 |
| Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma (NCT04588168) | The First Affiliated Hospital with Nanjing Medical University | 2018-01-01 |
| CD155 in Bladder Cancer (NCT03789682) | Fudan University | 2018-01-01 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors (NCT03289962) | Genentech, Inc. | 2017-12-21 |
| Genomic Imprinting Testing for Diagnosis of Bladder Cancer (NCT03563443) | Changhai Hospital | 2017-12-15 |